BioCryst Pharmaceuticals stock gets a new science board

Published on 10/05/2026 at 23:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioCryst Pharmaceuticals stock closed at USD 8.17 on October 2, while the company formed a seven-member science board. Q2 revenue reached USD 218.25 million.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals stock closed at USD 8.17 on Nasdaq on October 2, 2026, up 0.62 percent for the session and valued at USD 2.1 billion. On October 5, BioCryst announced a seven-member Scientific Advisory Board to guide its rare-disease research and development strategy, giving the company a fresh framework for pipeline expansion.

Seven experts reshape research strategy

According to GlobeNewswire on October 5, 2026, the board includes seven scientific and industry leaders and will advise on pipeline expansion, external innovation, translational science, clinical development and regulatory strategy.

The move formalizes BioCryst's shift toward external innovation. The company's commercial base remains ORLADEYO, an oral once-daily treatment for hereditary angioedema, while its pipeline includes navenibart and BCX17725.

Q2 profit adds financial support

BioCryst's second-quarter 2026 revenue was USD 218.25 million, compared with USD 156.41 million in the first quarter, according to the Yahoo Finance transcript. The quarter produced USD 98.5 million in GAAP operating profit and diluted EPS of USD 0.30, versus a USD 701.6 million operating loss and diluted EPS of negative USD 2.98 in Q1.

The comparison needs context: Q2 revenue included USD 55.7 million from the upfront payment tied to the navenibart European license agreement. ORLADEYO revenue reached USD 158.2 million and grew 10 percent year over year, while full-year 2026 total revenue guidance rose to USD 690 million to USD 715 million.

Analyst targets remain above Nasdaq price

According to MarketBeat on September 15, 2026, 12 analysts assigned BioCryst a Moderate Buy consensus, with seven Buy ratings and five Holds. The average 12-month price target was USD 20.40, placing the target 149.7 percent above the October 2 closing price of USD 8.17.

MarketBeat reported on September 30, 2026, that JPMorgan raised its target from USD 12.00 to USD 13.00 while maintaining a Neutral rating. That target remains below the published consensus but above the latest Nasdaq close.

BioCryst stock stays below yearly high

BioCryst shares closed at USD 8.17 on Nasdaq on October 2, 2026, with volume of 6,148,675 shares. The stock stood 27.2 percent below its 52-week high of USD 11.22 and above its 52-week low of USD 6.00.